advertisement
Morgan JE 21
Showing records 1 to 21 | Display all abstracts from Morgan JE120162 Oral nicotinamide provides robust, dose-dependent structural and metabolic neuroprotection of retinal ganglion cells in experimental glaucoma
Cimaglia G
Acta neuropathologica communications 2024; 12: 137
121417 Patient preferences for ocular hypertension monitoring: a discrete choice experiment
Wu H
BMJ open ophthalmology 2024; 9:
119730 Validating and Updating the OHTS-EGPS Model Predicting 5-year Glaucoma Risk among Ocular Hypertension Patients Using Electronic Records
Wright DM
Ophthalmology. Glaucoma 2024; 0:
121417 Patient preferences for ocular hypertension monitoring: a discrete choice experiment
Hernández R
BMJ open ophthalmology 2024; 9:
120162 Oral nicotinamide provides robust, dose-dependent structural and metabolic neuroprotection of retinal ganglion cells in experimental glaucoma
Tribble JR
Acta neuropathologica communications 2024; 12: 137
119730 Validating and Updating the OHTS-EGPS Model Predicting 5-year Glaucoma Risk among Ocular Hypertension Patients Using Electronic Records
Azuara-Blanco A
Ophthalmology. Glaucoma 2024; 0:
120162 Oral nicotinamide provides robust, dose-dependent structural and metabolic neuroprotection of retinal ganglion cells in experimental glaucoma
Votruba M
Acta neuropathologica communications 2024; 12: 137
121417 Patient preferences for ocular hypertension monitoring: a discrete choice experiment
Crabb DP
BMJ open ophthalmology 2024; 9:
119730 Validating and Updating the OHTS-EGPS Model Predicting 5-year Glaucoma Risk among Ocular Hypertension Patients Using Electronic Records
Cardwell C; Montesano G
Ophthalmology. Glaucoma 2024; 0:
120162 Oral nicotinamide provides robust, dose-dependent structural and metabolic neuroprotection of retinal ganglion cells in experimental glaucoma
Williams PA
Acta neuropathologica communications 2024; 12: 137
121417 Patient preferences for ocular hypertension monitoring: a discrete choice experiment
Gazzard G; Harper RA
BMJ open ophthalmology 2024; 9:
120162 Oral nicotinamide provides robust, dose-dependent structural and metabolic neuroprotection of retinal ganglion cells in experimental glaucoma
Morgan JE
Acta neuropathologica communications 2024; 12: 137
119730 Validating and Updating the OHTS-EGPS Model Predicting 5-year Glaucoma Risk among Ocular Hypertension Patients Using Electronic Records
Crabb DP; Gazzard G
Ophthalmology. Glaucoma 2024; 0:
121417 Patient preferences for ocular hypertension monitoring: a discrete choice experiment
King A
BMJ open ophthalmology 2024; 9:
119730 Validating and Updating the OHTS-EGPS Model Predicting 5-year Glaucoma Risk among Ocular Hypertension Patients Using Electronic Records
King AJ
Ophthalmology. Glaucoma 2024; 0:
121417 Patient preferences for ocular hypertension monitoring: a discrete choice experiment
Morgan JE
BMJ open ophthalmology 2024; 9:
119730 Validating and Updating the OHTS-EGPS Model Predicting 5-year Glaucoma Risk among Ocular Hypertension Patients Using Electronic Records
Hernández R
Ophthalmology. Glaucoma 2024; 0:
121417 Patient preferences for ocular hypertension monitoring: a discrete choice experiment
Takwoingi Y
BMJ open ophthalmology 2024; 9:
119730 Validating and Updating the OHTS-EGPS Model Predicting 5-year Glaucoma Risk among Ocular Hypertension Patients Using Electronic Records
Morgan JE
Ophthalmology. Glaucoma 2024; 0:
121417 Patient preferences for ocular hypertension monitoring: a discrete choice experiment
Azuara-Blanco A; Watson V; Watson V
BMJ open ophthalmology 2024; 9:
119730 Validating and Updating the OHTS-EGPS Model Predicting 5-year Glaucoma Risk among Ocular Hypertension Patients Using Electronic Records
Higgins B; Takwoingi Y;
Ophthalmology. Glaucoma 2024; 0:
